𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study

✍ Scribed by GianPiero Benetti; Mauro Borzio; Giuliano Ramella; Giorgio Bellati; Silvia Fargion; Alberto Colombo; Guido Croce; Carlo Iamoletti; Federico Balzola; Mario Rizzetto; GEL (Gruppo Epatologico Lombardo)

Publisher
Springer Milan
Year
2006
Tongue
English
Weight
98 KB
Volume
1
Category
Article
ISSN
1828-0447

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1b study of pegylated interferon l
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
✍ Andrew J. Muir; Mitchell L. Shiffman; Atif Zaman; Boris Yoffe; Andrew de la Torr 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 678 KB

Interferon lambda 1 (IFN-k1) is a type III IFN that produces intracellular responses similar to those of IFN-a but in fewer cell types because of differences in the receptor distribution pattern, and this could potentially result in an improved safety profile. This was an open-label three-part study

A randomised controlled trial of recombi
A randomised controlled trial of recombinant interferon-γ in chinese patients with chronic hepatitis B virus infection
✍ Johnson Y. N. Lau; Dr. C. L. Lai; P. C. Wu; H. T. Chung; Anna S. F. Lok; H. J. L 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 433 KB

## Abstract Nineteen Chinese patients with chronic hepatitis B virus (HBV) infection, seropositive for HBV e antigen (HBeAg) and HBV DNA on at least three occasions in 6 months, were randomised to receive either recombinant human interferongamma (rlFNγ) 0.1 mg/m^2^ intramuscularly thrice weekly for

Efficacy of low-dose intermittent interf
Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy
✍ Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

## Abstract The efficacy of interferon (IFN) monotherapy for non‐responders to pegylated interferon (PEG‐IFN) plus ribavirin (RBV) combination therapy is still unclear. To evaluate the impact of IFN monotherapy on biochemical response, 200 consecutive patients infected with HCV genotype 1b, who rec

A mutation in the interferon sensitivity
A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1b
✍ Mutsumi Murayama; Yoshiaki Katano; Isao Nakano; Masatoshi Ishigami; Kazuhiko Hay 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB 👁 2 views

## Abstract The interferon sensitivity‐determining region (ISDR) is useful as a predictive marker of the response to interferon (IFN) therapy for chronic hepatitis patients with a Japan‐specific subtype (J‐type) of hepatitis C virus (HCV) genotype 1b. This marker is not useful for predicting respon

Pretreatment virus load and multiple ami
Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity–determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection
✍ K Chayama; A Tsubota; M Kobayashi; K Okamoto; M Hashimoto; Y Miyano; H Koike; M 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 256 KB 👁 3 views

biochemical and histological improvement. 3,4 Several factors Hepatitis C virus (HCV) genotype 1b and high precan predict a poor response to interferon therapy, e.g., high treatment virus load are predictive factors of poor repretreatment virus load, genotype 1b, advanced histological sponse to inte